Combining Pharmacological and Psychological Treatments for Binge Eating Disorder: Current Status, Limitations, and Future Directions

Current Psychiatry Reports

Volumn 18, Issue 6, 2016, Pages

  Grilo, Carlos M ^a   Reas, Deborah L ^b,c   Mitchell, James E ^d,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d NEUROPSYCHIATRIC RESEARCH INSTITUTE   (United States)

^e UND School of Medicine & Health Sciences Southeast Campus   (United States)

Author keywords

Behavioral weight loss; Binge eating disorder; Cognitive behavioral therapy; Medication; Obesity; Pharmacotherapy

Indexed keywords

DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; METHYLPHENIDATE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZONISAMIDE; ANTIOBESITY AGENT; FRUCTOSE; LACTONE;

BEHAVIOR THERAPY; BINGE EATING DISORDER; CLINICAL PRACTICE; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PREVALENCE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BINGE-EATING DISORDER; BULIMIA NERVOSA; COGNITIVE THERAPY; OBESITY; PSYCHOLOGY; TRENDS;

ANTI-OBESITY AGENTS; BINGE-EATING DISORDER; BULIMIA NERVOSA; COGNITIVE THERAPY; FRUCTOSE; HUMANS; LACTONES; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

EID: 84963772071     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-016-0696-z     Document Type: Review

References (42)

1. APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
2. Hudson JI, Hiripi E, Pope Jr HG, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61:348–58.
3. Kessler RC, Berglund PA, Chiu WT, Deitz AC, Hudson JI, Shahly V, et al. The prevalence and correlates of binge eating disorder in the World Health Organization world mental health surveys. Biol Psychiatry. 2013;73:904–14.
4. Marques L, Alegria M, Becker AE, Chen CN, Fang A, Chosak A, et al. Comparative prevalence, correlates of impairment, and service utilization for eating disorders across US ethnic groups: implications for reducing ethnic disparities in health care access for eating disorders. Int J Eat Disord. 2011;44:412–20.
5. Grilo CM, Masheb RM, White MA. Significance of overvaluation of shape/weight in binge-eating disorder: comparative study with overweight and bulimia nervosa. Obesity. 2010;18:499–504.
6. Hudson J, Lalonde JK, Berry JM, Pindyck LJ, Bulik CM, Crow SJ, et al. Binge-eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry. 2006;63:313–9.
7. APA. Diagnostic and statistical manual of mental disorders. 4th ed. Arlington: American Psychiatric Publishing; 1994.
8. Devlin MJ. Binge-eating disorder and obesity. A combined treatment approach. Psychiatr Clin N Am. 2001;24:325–35.
9. NICE. Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa, and related eating disorders. NICE Clinical Guideline No. 9. London, 2004.
10. Iacovino JM, Gredysa DM, Altman M, Wilfley DE. Psychological treatments for binge eating disorder. Curr Psychiatr Rep. 2012;14:432–46.
11. Wilson GT, Grilo CM, Vitousek KM. Psychological treatment of eating disorders. Am Psychol. 2007;62:199–216.
12. Wilson GT, Zandberg LJ. Cognitive-behavioral guided self-help for eating disorders: effectiveness and scalability. Clin Psychol Rev. 2012;32:343–57.
13. Wilson GT, Wilfley DE, Agras WS, Bryson SW. Psychological treatments of binge eating disorder. Arch Gen Psychiatry. 2010;67:94–101.
14. Hilbert A, Bishop ME, Stein RI, Tanofsky-Kraff M, Swenson AK, Welch RR, et al. Long-term efficacy of psychological treatments for binge eating disorder. Br J Psychiatry. 2012;200:232–7.
15. Grilo CM, Masheb RM, Wilson GT, Gueorguieva R, White MA. Cognitive-behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with binge-eating disorder: a randomized controlled trial. J Consult Clin Psychol. 2011;79:675–85.
16. Brownley KA, Peat CM, La Via M, Bulik CM. Pharmacological approaches to the management of binge eating disorder. Drugs. 2015;75:9–32.
17. McElroy SL, Guerdjikova AI, Mori N, Keck PE. Psychopharmacologic treatment of eating disorders: emerging findings. Curr Psychiatr Rep. 2015;17:35.
18. Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity. 2008;16:2024–38.
19. Reas DL, Grilo CM. Pharmacological treatment of binge eating disorder: update review and synthesis. Expert Opin Pharmacother. 2015;16:1463–78.
20. Agras WS, Telch CF, Arnow B. Weight loss, cognitive-behavioral, and desipramine treatments in binge eating disorder: an additive design. Behav Ther. 1994;25:225–38.
21. Laederach-Hofmann K, Graf C, Horber F, Lippuner K, Lederer S, Michel R, et al. Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord. 1999;26:231–44.
22. Ricca V, Mannucci E, Mezzani B, Moretti S, Di BM, Bertelli M, et al. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom. 2001;70:298–306.
23. Devlin MJ, Goldfein JA, Petkova E, Jiang H, Raizman PS, Wolk S, et al. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res. 2005;13:1077–88.
24. Devlin MJ, Goldfein JA, Petkova E, Liu L, Walsh BT. Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up. Obesity. 2007;15:1702–9.
25. Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, Chabloz M, Kammer A, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005;13:1701–8.
26. Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2005;57:1193–201.
27. Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57:301–9.
28. Grilo CM, Crosby RD, Wilson GT, Masheb RM. 12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder. J Consult Clin Psychol. 2012;80:1108–13. RCT reported 12-month follow-up data after completing and discontinuing 16-week acute treatments with fluoxetine, CBT + fluoxetine, or CBT + placebo. Findings indicate the significantly superior specific durability of CBT relative to fluoxetine and that fluxotine does not enhance CBT outcomes after treatment completion.
29. Claudino AM, de Oliveira IR, Appolinario JC, Cordas TA, Duchesne M, Sichieri R, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68:1324–32. RCT reported that the addition of topiramate to CBT enhanced binge eating and weight loss outcomes in patients with BED at post-treatment.
30. Ricca V, Castellini G, Lo Sauro C, Rotella CM, Faravelli C. Zonisamide combined with cognitive behavioral therapy in binge eating disorder: a one-year follow-up study. Psychiatry. 2009;6:23–8.
31. Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther. 2013;51:167–75. RCT performed in a community-based setting serving Latinos reported that adding orlistat to BWL produced greater weight loss than adding placebo among obese patients without BED but not among those with BED. 50 % of BED patients maintained binge-abstinence at 6-month follow-ups; despite such improvements, BED was a negative predictor of some treatment outcomes.
32. Grilo CM, Masheb RM, White MA, Gueorguieva R, Barnes RD, Walsh BT, et al. Treatment of binge eating in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication. Behav Res Ther. 2014;58:1–9.
33. National Institute of Mental Health; University of Virginia. Adding guided self-help group therapy to the Alli weight loss program in treating binge eating disorder. In: ClinicalTrials.gov [Internet]. Bethesda (MD). National Library of Medicine (US); 2000 [cited 2016 Feb 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT00601354?term=NCT00601354&rank=1.
34. National Institute of Mental Health; University of Virginia. A comparison of methylphenidate and cognitive behavioural therapy for the treatment of binge eating disorder. In: ClinicalTrials.gov [Internet]. Bethesda (MD). National Library of Medicine (US); 2000 [cited 2016 Feb 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT01921582.
35. National Institute of Mental Health; University of Virginia. Treatment of obesity and binge eating: behavioral weight loss versus stepped care. In: ClinicalTrials.gov [Internet]. Bethesda (MD). National Library of Medicine (US); 2002 [cited 2016 Feb 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT00829283.
36. Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley V, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry. 2008;165:51–8.
37. Mitchell JE, Fletcher L, Harrison K, Mussell MP, Seim H, Crosby RD, et al. The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa. J Clin Psychopharmacol. 2001;21:298–304.
38. Walsh BT, Fairburn CG, Mickley DE, Sysko R, Parides MK. Treatment of bulimia nervosa in a primary care setting. Am J Psychiatry. 2004;161:556–61.
39. McElroy SL, Shapira NA, Arnold LM, Keck PE, Rosenthal NR, Wu SC, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004;65:1463–9.
40. McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatr. 2015;72:235–46. Large multi-site RCT reported short-term efficacy of 50 and 70 mg LDX relative to placebo at 11-weeks in patients with moderate-to-severe BED.
41. McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2015. doi:10.1038/npp.2015.275. Two large phase 3 RCTs reported short-term efficacy of 50–70 mg/day dosing of LDX relative to placebo in patients with moderate-to-severe BED. LDX associated with binge abstinence rates of 40 and 36% in the two trials at the 11-week post-treatment evaluation. These data supported FDA approval of this medication for BED.
42. Grilo CM, Masheb RM, Crosby RD. Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder. J Consult Clin Psychol. 2012;80:897–906. Important methodological paper demonstrating analyses of predictors/moderators of treatment outcomes. Findings suggested that overvaluation of shape/weight and negative affect are significant moderators of treatment outcome; patients with these characteristics fare better in CBT and in fluoxetine treatments.